Fig. 1: Adjuvant comparison of anti-EBOV-GP serum antibody titers post-immunization with RABV-vectored FILORAB1 vaccine.
From: Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge
a EBOV-GP specific antibody ELISA of sera from C57BL/6 mice immunized with a prime-boost schedule at day 0 and week 4 with FILORAB1 unadjuvanted or with GLA-SE, SE, GLA-alum, or alum at 1 week, b 2 weeks, c 4 weeks, d 5 weeks, and e 7 weeks post-immunization reported as average half-maximal effective concentration (EC50) titer (bars) determined from individual mouse serum (symbols) ELISA curves. f EBOV-GP specific antibody responses over time from 1 to 7 weeks post-immunization separated by the boost immunization at week 4. g Neutralizing antibody titers at week 7 reported as half-maximal inhibitory concentration (IC50) of serum dilution. NHP survivor sera (black star) is pooled from a previous EBOV challenge experiment. The WHO standard (black asterisk) consists of convalescent plasma pool. Error bars represent the standard deviation (SD) from the mean. Statistics are by one-way ANOVA with post hoc Tukey’s test of log-transformed EC50 or IC50 titers. p > 0.1234 (ns), p < 0.0332 (*), p < 0.0021 (**), p < 0.0002 (***), p < 0.0001 (****).
